Illumina Inc. (ILMN) Given Average Rating of “Hold” by Brokerages
Illumina Inc. (NASDAQ:ILMN) has been assigned an average rating of “Hold” from the twenty-seven ratings firms that are covering the company. Three analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $153.50.
Several analysts have commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Illumina from $185.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 27th. Cantor Fitzgerald restated a “hold” rating on shares of Illumina in a research note on Wednesday, June 29th. Vetr cut shares of Illumina from a “buy” rating to a “hold” rating and set a $187.86 price objective for the company. in a research note on Monday, October 10th. BTIG Research restated a “neutral” rating on shares of Illumina in a research note on Wednesday, October 12th. Finally, Argus lifted their price objective on shares of Illumina from $175.00 to $185.00 and gave the company a “buy” rating in a research note on Monday, August 8th.
Shares of Illumina (NASDAQ:ILMN) traded up 1.780% during midday trading on Wednesday, hitting $147.805. The company had a trading volume of 488,117 shares. The company has a market capitalization of $21.67 billion, a price-to-earnings ratio of 50.618 and a beta of 0.47. Illumina has a 12-month low of $127.10 and a 12-month high of $196.47. The company’s 50-day moving average price is $169.54 and its 200 day moving average price is $155.73.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/illumina-inc-ilmn-given-average-rating-of-hold-by-brokerages.html
Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, July 26th. The life sciences company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.13. The company earned $600 million during the quarter, compared to analysts’ expectations of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. Illumina’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same period last year, the business earned $0.80 EPS. Equities research analysts predict that Illumina will post $3.53 earnings per share for the current fiscal year.
In other news, Director Daniel Bradbury sold 600 shares of the stock in a transaction dated Friday, October 7th. The shares were sold at an average price of $184.36, for a total transaction of $110,616.00. Following the sale, the director now owns 17,065 shares of the company’s stock, valued at $3,146,103.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert S. Epstein sold 300 shares of the stock in a transaction dated Tuesday, September 20th. The stock was sold at an average price of $174.29, for a total transaction of $52,287.00. Following the sale, the director now directly owns 6,924 shares in the company, valued at approximately $1,206,783.96. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the company. Virginia Retirement System acquired a new stake in shares of Illumina during the first quarter valued at about $385,000. NN Investment Partners Holdings N.V. acquired a new stake in shares of Illumina during the first quarter valued at about $403,000. Menta Capital LLC acquired a new stake in shares of Illumina during the first quarter valued at about $603,000. Aviva PLC boosted its stake in shares of Illumina by 2.4% in the first quarter. Aviva PLC now owns 75,222 shares of the life sciences company’s stock valued at $12,194,000 after buying an additional 1,749 shares in the last quarter. Finally, Rafferty Asset Management LLC boosted its stake in shares of Illumina by 10.9% in the first quarter. Rafferty Asset Management LLC now owns 5,184 shares of the life sciences company’s stock valued at $840,000 after buying an additional 508 shares in the last quarter. 95.24% of the stock is currently owned by institutional investors and hedge funds.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.